ERBB2 and breast cancer: To address this problem, we carried out this study to compare the effectiveness of TCH + Py, TCH, and TCHP regimens for the neoadjuvant treatment of HER2-positive breast cancer, and the results showed a pCR rate of 55.6%, 32.7%, and 56.6%, respectively.